UroGen Pharma Ltd. — Director's Dealing 2019

Jan 9, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-01-03

Reporting Person: Barrett Elizabeth A. (Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-01-03	Employee Stock Option (right to buy)	$47.57	A	277432	Acquired	2029-01-03	Ordinary Shares (277432)	Direct
2018-01-03	Restricted Stock Unit	$	A	317065	Acquired		Ordinary Shares (317065)	Direct

Footnotes

F1: 33% of the shares underlying the stock option will vest on January 3, 2020 and 2.778% of the remaining shares will vest in equal monthly installments thereafter.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3: 33% of the RSUs will vest on January 3, 2020 and the remaining RSUs will vest 2.778% in equal monthly installments thereafter.